Healthcare ❯ Pharmaceuticals

Drug Approval

FDA Clinical Trials FDA Regulations Regulatory Agencies Mifepristone Generic Drugs FDA Approval NHS Regulatory Affairs NHS Policies

FDA Approves Zanvastro as First Treatment for Alexander Disease

Validation of Ionis’s antisense approach shifts attention to U.S. launch execution, real-world durability, pricing, and patient access

Medsafe Authorises Two Psychiatrists to Give MDMA Therapy for Severe PTSD

Judge Pauses Texas-Florida Mifepristone Lawsuit Pending FDA Review

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Anvisa Approves First Non‑Hormonal Drug for Menopausal Hot Flashes

Germany Approves Cannabis-Based Drug Exilby for Neuropathic Back Pain

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

FDA Expands Tzield Use to Delay Type 1 Diabetes in Children Ages 1 to 7

Italy Opens SSN Coverage for Cytisine Quit-Smoking Pill Now Available in Pharmacies

Hims & Hers Soars as Novo Nordisk Reinstates Supply Deal for Ozempic and Wegovy

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Shareholder Law Firms Expand Probes of Corcept After FDA CRL for Relacorilant

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Bristol Myers Enters 2026 With Eliquis Medicaid Pact, Opdivo Qvantig Rollout, and Divergent Analyst Views